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A B S T R A C T
Pathogenic variants in pre-messenger RNA (pre-mRNA) splicing factor 31, PRPF31, are the second most common genetic cause of autosomal dominant retinitis
pigmentosa (adRP) in most populations. This remains a completely untreatable and incurable form of blindness, and it can be difficult to predict the clinical course of
disease. In order to design appropriate targeted therapies, a thorough understanding of the genetics and molecular mechanism of this disease is required. Here, we
present the structure of the PRPF31 gene and PRPF31 protein, current understanding of PRPF31 protein function and the full spectrum of all reported clinically
relevant variants in PRPF31. We delineate the correlation between specific PRPF31 genotype and RP phenotype, suggesting that, except in cases of complete gene
deletion or large-scale deletions, dominant negative effects contribute to phenotype as well as haploinsufficiency. This has important impacts on design of targeted
therapies, particularly the feasibility of gene augmentation as a broad approach for treatment of PRPF31-associated RP. We discuss other opportunities for therapy,
including antisense oligonucleotide therapy and gene-independent approaches and offer future perspectives on treatment of this form of RP.
1. Introduction
1.1. Pre-mRNA splicing
Human pre-mRNA splicing factor 31 (PRPF31) is a component of
the spliceosome, the huge macromolecular ribonucleoprotein (RNP)
complex which catalyses the splicing of pre-messenger RNAs (pre-
mRNAs) to remove introns and produce mature mRNAs(Will and
Luhrmann, 2011).
Pre-mRNA splicing is a core function in all eukaryotic cells. The vast
majority of genes have multiple exons and introns, and around 95% of
these multiexon genes undergo alternative splicing(Pan et al., 2008).
Alternative splicing allows increased organism complexity without in-
creasing genome size, and helps to explain the c-value paradox; the
observation that phenotypic complexity in the eukaryotic domain is not
proportional to genome size.
The spliceosome is composed of 5 small nuclear RNAs (snRNAs),
U1–U5, and many proteins, together making 5 snRNPs. In the process of
splicing, U1snRNP recognises and binds the splice donor site (the 5’
splice site), and promotes the binding of U2snRNP to the branch site.
Independently of this, the U4/U6.U5 tri-snRNP forms in the cell, and is
recruited to the pre-mRNA, where U6snRNP replaces U1snRNP. This
forms the catalytically active spliceosome, which cuts away the intron
and joins the exons through two transesterification reactions (Fig. 1).
1.2. PRPF31, splicing and retinal disease
The S. cerevisiae yeast homologue of PRPF31, Prp31, was cloned and
identified as a key splicing factor in 1996 (Weidenhammer et al., 1996),
and later was shown to be essential for the association of the U4/U6.U5
tri-snRNP with pre-spliceosomes(Weidenhammer et al., 1997). It was
subsequently found to play a role in both splicing and meiosis in S.
pombe(Bishop et al., 2000). Unexpectedly, in 2001, it was discovered
that heterozygous pathogenic variants in PRPF31 are associated with
retinitis pigmentosa (RP), an inherited retinal dystrophy affecting
1:2000 to 1:3500 people worldwide(Vithana et al., 2001). This was
surprising because pre-mRNA splicing factors are highly conserved
from yeast to man with a core function in all cells. Intuitively, it would
be expected that a defect in a core spliceosomal protein should have an
impact on all cells, not just retinal cells.
The original paper described seven different pathogenic variants in
four families and three simplex cases. These included mutations in the
region of the splice site, leading to inactivation of a splice acceptor site,
inactivation of a splice donor site, two missense changes, three frame-
shift variants and an in-frame duplication(Vithana et al., 2001).
Since then, and particularly since the advent of massively parallel
sequencing technologies, it has become clear that pathogenic variants
in PRPF31 are a major cause of autosomal dominant RP (adRP). Indeed
they are the second most common genetic cause of adRP in most
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populations, accounting for 6% of US cases (Sullivan et al., 2013), 8%
of Spanish, French and French-Canadian cases (Martin-Merida et al.,
2018; Audo et al., 2010; Coussa et al., 2015), 8.9% of cases in North
America (Daiger et al., 2014), 10–11.1% of Chinese cases (Lim et al.,
2009; Xu et al., 2012) and 10.5% of Belgian cases(Van Cauwenbergh
et al., 2017).
However, this is likely to be an underestimate due to non-pene-
trance of this form of RP (Rose and Bhattacharya, 2016). It is common
to see very variable severity of eye disease in different members of the
same family with the same pathogenic PRPF31 variant. Furthermore,
obligate carriers may be totally asymptomatic, showing complete non-
penetrance. This complicates attempts to co-segregate PRPF31 variants
with clinical disease and makes genetic diagnosis difficult, likely con-
tributing to an underestimation of the prevalence of RP associated with
PRPF31 variants.
The genetic mechanism controlling incomplete penetrance remains
unclear, but a fairly consistent observation of correlation between ex-
pression level of the non-mutant copy of PRPF31 and disease severity
has been reported.(Rio Frio et al. 2008b, 2009; Rivolta et al., 2006).
This varied expression can be explained by a number of factors in-
cluding:
- expression quantitative trait loci (eQTLs) (on ch.14q21-23) in trans
with PRPF31(Rio Frio et al., 2008a)
- variable level of expression of CNOT3, a trans-acting epistatic factor
which is genetically linked to PRPF31 and regulates expression of
PRPF31. CNOT3 encodes a subunit of the Ccr4-not transcription
complex, which binds to the promoter of PRPF31 and represses
Fig. 1. Schematic representation of the first four steps of pre-mRNA splicing by the major spliceosome, with PRPF31 shown in red. In step 1, U1snRNP
recognises and binds the splice donor site (the 5′ splice site). In step 2, binding of U1snRNP to the splice donor site promotes the binding of U2snRNP to the branch
site. Independently of this, the U4/U6.U5 tri-snRNP forms in the cell. In step 3, the U4/U6.U5 tri-snRNP is recruited to the pre-mRNA, where U6snRNP replaces
U1snRNP. This forms the catalytically active spliceosome, which in step 4 cuts away the intron and joins the exons through two transesterification reactions. (For
interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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transcription of PRPF31. An intronic variant in CNOT3 determines
its level of expression and thus how efficiently PRPF31 expression is
downregulated. The alleles of CNOT3 inherited determine the ex-
pression of non-mutant PRPF31 and thus whether a person will be
affected by the disease(Venturini et al., 2012; Rose et al., 2014).
- the number of minisatellite repeat elements (MSR1) adjacent to the
PRPF31 core promoter, which determines the level of transcriptional
repression of the non-mutant PRPF31.4 MSR1 copies are associated
with higher non-mutant PRPF31 expression and are found in non-
symptomatic carriers only(Rose et al., 2016).
On the basis of these observations, the mechanism of incomplete pe-
netrance in this form of RP has been described as ‘variant haploinsuffi-
ciency’, in which the absence of a second wild-type PRPF31 allele is
sometimes sufficient to produce disease, and sometimes is not, depending
on the nature of the mutant allele inherited and the nature of the wild-type
allele inherited. So the severity of the resultant disease depends on both the
type of mutant allele inherited (ie complete loss-of-function, gain-of-func-
tion or hypomorphic), the level at which this allele is expressed, and the
level at which the wild-type allele is expressed (Rose and Bhattacharya,
2016). This form of variant haploinsufficiency has only been described in a
very few Mendelian disorders, making the mechanism of variable pene-
trance in this disease quite unique (Rose and Bhattacharya, 2016).
1.3. PRPF31 gene and PRPF31 protein structure
PRPF31 is a 16.3 kb gene on chromosome 19 which encodes 9 dif-
ferent transcripts, 6 of which are protein coding. The largest, most
widely expressed transcript consists of 14 exons; 1 non-coding and 13
coding, which produces a 499 amino acid protein of 55 kDa in size, pre-
mRNA splicing factor 31, PRPF31.
PRPF31 contains several important functional domains; the flexible
loop, Nop domain, coiled-coil domain and tip. Recent advances in spec-
troscopy and microscopy methods such as NMR and cryo-electron mi-
croscopy have allowed accurate resolution of the crystal structure of
proteins of the spliceosome, including PRPF31, in their native conforma-
tions at different points during splicing(Agafonov et al., 2016; Bertram
et al. 2017a, 2017b; Haselbach et al., 2018). These studies have revealed
that PRPF31 contains a conserved Nop domain (residues 222–254 and
278–307), with regions for binding protein and RNA(Liu et al., 2007). This
Nop domain has relaxed sequence conservation in PRPF31, but it retains
high specificity for binding U4 or U4atac and 15.5K protein (Liu et al.,
2007). The flexible loop (residues 256–265) protects the exposed C4’
atoms of residues 37 and 38 from attack by free radicals, to protect the
RNA without directly contacting it(Liu et al., 2007). The protein also has
several phosphorylation sites, clustered in the C-terminus(Liu et al., 2007).
PRPF31 contains a nuclear localisation sequence, NLS, which allows it to
be targeted to the nucleus after translation (Fig. 2).
1.4. PRPF31 protein function
PRPF31 is required for tri-snRNP assembly in human cells
(Makarova et al., 2002). With PRFP6, PRPF31 forms an essential
connection between the U4/U6 and U5 snRNPs. siRNA knockdown of
PRPF31 results in inhibition of tri-snRNP formation and nuclear accu-
mulation of U5 mono-snRNPs and U4/U6 di-snRNPs containing U4/U6
proteins and the U4/U6 recycling factor p110(Schaffert et al., 2004).
The specific function of PRPF31 in retinal cells remains less clear. It
remains unclear whether the photoreceptor cells are the primary affected
cells in RP associated with PRPF31, with a number of studies suggesting
that the RPE is the primary affected tissue(Farkas et al., 2014; Hamieh
and Nandrot, 2019; Valdés-Sánchez et al., 2019). Retinal cells are highly
metabolically active, with a high demand for ATP and protein anabolism
as around 10% of protein from photoreceptor outer segments is shed
every day. Rates of metabolism in photoreceptors are similar to dividing
tumour cells, and undergo extensive anaerobic glycolysis rather than
oxidative phosphorylation to produce energy, in what is termed the
‘Warburg effect’(Ng et al., 2015; Rajala et al., 2016). The reliance on
glycolysis seems to promote efficient protein anabolism in photo-
receptors(Chinchore et al., 2017). However, the photoreceptors still re-
quire mitochondria to produce a proportion of their ATP via oxidative
phosphorylation(Grenell et al., 2019). It has been postulated that pho-
toreceptor cells have a greater demand for pre-mRNA splicing factors to
meet this metabolic demand, but evidence to support this hypothesis is
inconsistent. Some studies have reported higher levels of PRPF31 ex-
pression in retina than in other tissues (Cao et al., 2011) but other studies
show a consistent level of expression in all tissues, with no significantly
higher expression in retina or any other tissue(Yuan et al., 2005).
Related to this elevated rate of oxidative phosphorylation, retinal
cells are subject to much higher rates of oxidative damage, including
UV-induced photooxidative damage, which may explain the retinal-
specific phenotype of RP associated with pre-mRNA splicing factor
mutations.(Comitato et al., 2007; Shinde et al., 2016; Jin et al., 2011;
Schmidt-Kastner et al., 2008). In patients expressing mutant forms of
pre-mRNA splicing factors, it has been shown that proteins have re-
duced solubility, which can lead to formation of protein aggregates, and
it has been suggested that the environment of UV-induced photo-
oxidative damage in the photoreceptors makes these cells specifically
prone to degeneration(Wheway et al., 2019; Valdés-Sánchez et al.,
2019; Wilkie et al., 2006; Yin et al., 2011; Bryant et al., 2019). This
splicing-independent disease mechanism is appealing because there is
inconsistent evidence of splicing defects in cells carrying PRPF31 mu-
tations. Studies seem to suggest that expression of mutant PRPF31 af-
fects splicing of some transcripts but not others.
Immunoprecipitation of splicing complexes from PRPF31 mutant
retinal cells showed that mutant PRPF31 proteins significantly in-
hibited pre-mRNA splicing of intron 3 in the rhodopsin (RHO) gene
(Yuan et al., 2005). In primary retinal cell cultures, expression of the
mutant PRPF31 proteins reduced total RHO expression and caused
apoptosis of rhodopsin-positive retinal cells(Alagramam et al., 2001). In
a study of patient lymphoblastoid cell lines, splicing efficiency of RPGR
intron 9 was significantly decreased in PRPF31 mutant cell lines but no
consistent decrease in the splicing efficiency of U12 and noncanonical
U2 introns was seen in PRPF31 mutant cells(Ivings et al., 2008). In a
minigene study, assays using the RHO intron 3 minigene template re-
vealed a direct negative effect on splicing efficiency of mutant PRPF31.
Fig. 2. Schematic representation of the protein and cDNA structure of PRPF31, showing major structural domains encoded by each exon.
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However, no effect of the mutation on splicing efficiency could be de-
tected using the longer GNAT1 minigene template or using a full-length
RHO transcript, splicing of which had an efficiency of 100%. Similarly,
no unspliced RHO transcripts could be detected in RNA from human
retina(Wilkie et al., 2008).
Using novel stem cell technologies, recent studies in retinal orga-
noids and retinal pigment epithelium (RPE) derived from induced
pluripotent stem cells (iPSCs) from patients with PRPF31 mutations
show decreased efficiency of splicing of E1A minigene(Buskin et al.,
2018). RPE from patient iPSCs also show a substantial downregulation
of SART1, a U5 snRNP protein important for the formation of the pre-
catalytic spliceosome, but no changes in the expression of the U5 pro-
tein PRPF8 or the U4/U6 protein PRPF4(Buskin et al., 2018). In both
RPE and retinal organoids derived from PRPF31 patients, the most
significantly mis-spliced genes were genes involved in pre-mRNA and
alternative mRNA splicing via the spliceosome(Buskin et al., 2018).
Alongside these findings, it was observed that retinal organoids from
patients showed differential expression of actin cytoskeleton, ciliary
membrane, primary cilium, photoreceptor inner and outer segment, axon
terminal and phototransduction proteins. Furthermore, patient organoids
showed an enrichment of mis-spliced centriole and microtubule organi-
sation genes. This suggests that centriole and ciliogenesis and cilium
function are all regulated by alternative splicing in the retina, and this is
defective in patients carrying PRPF31 mutations(Buskin et al., 2018).
These findings were confirmed in independent studies of splicing in
PRPF31 siRNA-treated human organotypic retinal cultures(Azizzadeh
Pormehr et al., 2019). This is in keeping with earlier studies from our-
selves, and others, which showed that siRNA knockdown of pre-mRNA
splicing factors including PRPF31 has a specific and significant effect on
ciliogenesis(Wheway et al., 2015; Kim et al., 2016). Further investigation
showed that these proteins localise to the base of the photoreceptor ci-
lium, classifying these conditions as retinal ciliopathies(Wheway et al.,
2015). Recent work developing PRPF31 gene augmentation therapy has
shown rescue of ciliogenesis in PRPF31 ± RPE cells derived from
human patient iPSCs after expression of wild-type PRPF31 delivered by
an AAV vector, further suggesting that PRPF31 plays a key role in reg-
ulating ciliogenesis in patients(Brydon et al., 2019).
Further work is needed to understand the nature of the splicing
factors’ involvement in ciliogenesis and cilium function in the retina,
and this work is ongoing. It is possible that PRPF31 and other splicing
factors have roles beyond splicing. Many proteins involved in splicing
have multiple functions in the cell, such as the proteins of the PRP19
complex which have roles in ubiquitination (Vander Kooi et al., 2006),
in DNA damage sensing (Grey et al., 1996; Marechal et al., 2014), DNA
damage repair (Zhang et al., 2005), mRNA export (Chanarat et al.,
2011) and in mitotic spindle assembly (Hofmann et al., 2013). PRPF31
has been shown to perform splicing-independent functions in mitotic
chromosome segregation, although this would not explain disease
phenotype in the post-mitotic retina. With deeper understanding of the
molecular mechanism of PRPF31 disease arise greater opportunities for
developing effective targeted therapies.
1.5. PRPF31 mutation spectrum
In order to fully understand the molecular mechanism of RP asso-
ciated with PRPF31 variants, it is necessary to fully understand the
genetics of this condition. This will aid accurate diagnostics, prog-
nostics and development of targeted therapies. To this end, we have
reviewed the literature and the major clinical variant database ClinVar
to summarise all reported pathogenic variants in PRPF31 (Table 1).
Mutations are spread throughout the gene, but are most common in
exons 6–10, particularly exons 7 and 8 (Fig. 3).
The majority of reported mutations in PRPF31 are presumed loss-of-
function variants including frameshift (51 different variants reported in
70 different families), splice site (30 variants in 52 families), nonsense
(30 variants in 40 families) or large-scale insertions or deletions (25
variants in 32 families), which are predicted to lead to complete loss of
expression of protein from the affected allele. PRPF31 is highly intol-
erant to loss-of-function with a probability of being loss-of-function
intolerant (pLI) score of 0.98 (Lek et al., 2016). A pLI score of> 0.9
indicates that a gene is intolerant of protein-truncating variation (Lek
et al., 2016) and thus loss-of-function variants in PRPF31 are highly
likely to cause disease through a haploinsufficiency disease mechanism
(discussed in more detail later). However, it is important to note that
whilst frameshift, consensus splice site, nonsense and large indel var-
iants are often assumed to cause loss-of-function, this is not always the
case, particularly when frameshift or nonsense variants are found in the
final exon or C-terminal portion of the penultimate exon; transcripts
from genes with such variants are likely to evade nonsense mediated
decay (Ziegler et al., 2019). At least 3 frameshift or nonsense mutations
in the final two exons of PRPF31 have been reported as pathogenic, but
functional study is required to confirm pathogenicity (Martin-Merida
et al., 2018; Huang et al., 2015). Similarly, consensus splice site mu-
tations are often also assumed to cause complete loss of wild-type
protein expression from the affected allele, when in fact the complex
mechanisms of alternative splicing may lead to production of a trun-
cated protein, particularly if the splicing change produces an in-frame
transcript. In several cases where mutations are assumed to be causing
loss-of-function through haploinsufficiency, in addition to presumed
loss-of-function variants, at least 19 missense variants have been re-
ported in PRPF31 as being pathogenic. Gene constraint metrics, which
provide quantitative measures of the extent to which a gene can tol-
erate change, indicate that PRPF31 gene is highly intolerant to missense
variants (Z = 3.27) (Samocha et al., 2014; Lek et al., 2016). Missense
mutations in PRPF31 tend to reduce the solubility of protein so it does
not translocate into nucleus efficiently after being translated in the
cytoplasm (Deery et al., 2002; Bryant et al., 2019; Wheway et al.,
2019), effectively leading to a loss of this protein. However, only 4
missense variants have been functionally studied in vitro, and a com-
prehensive study of reported missense variants is required to confirm
the functional effect of pathogenic variants, and indeed the patho-
genicity of reported variants. At least one variant originally described
as a missense variant was later confirmed to be affecting splicing (Rio
Frio et al., 2008b) and it is possible that other variants classified as
missense, both recognised pathogenic and those currently considered
non-pathogenic, may in fact be impacting upon splicing of PRPF31.
Furthermore, non-synonymous rare variants may impact on splicing. It
is therefore likely that the rate of pathogenic variants affecting splicing
in PRPF31 is underestimated.
1.6. Genotype-phenotype correlation
We reviewed the literature and recorded the age of onset of first
symptoms, and age of diagnosis, where it was reported alongside spe-
cific genetic variants. Age of onset of first symptoms (usually night-
blindness) is lowest in patients with nonsense, frameshift or indel var-
iants, with median age of onset between 8 and 12 years of age. Patients
with large deletions or splice variants tend to show first symptoms at a
slightly later median age of 20–24. Patients with in-frame duplications,
insertions or missense variants show the latest median age of onset of
first symptoms, around 27 years of age (Fig. 4a). The difference in age
of onset between the different types of mutation is statistically sig-
nificant (one-way ANOVA p = 5.76 × 10−5).
We also recorded the age of diagnosis where it was reported
alongside specific PRPF31 genetic variants. In this case, patients with
nonsense, frameshift or splice variants were diagnosed at a median age
of 20–30 years (usually because of loss of peripheral vision alongside
night blindness), whereas patients with missense variants, in-frame
deletions or large deletions tended to be diagnosed between the ages of
45 and 50 (Fig. 4b). The difference in age of diagnosis between the
different types of mutation is statistically significant (one-way ANOVA
p = 0.030).
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There is no significant correlation between location of the variant in
the gene and age of onset of symptoms or age of diagnosis.
It is an interesting observation, made in several studies and con-
firmed here, that patients with large-scale deletions, including multi-
exon and whole gene deletions have the latest age of diagnosis. There is
a clear difference in age of diagnosis of patients with large-scale dele-
tions compared to patients with nonsense mutations or splice mutations
although this is not statistically significant after correction for multiple
testing (two-tailed unpaired t-test p = 0.016 and p = 0.032 respec-
tively, p = 0.24 and p = 0.48 respectively after Bonferroni correction)
(Fig. 4b). It could be postulated that there is an element of dominant
negative effect at play in cases of nonsense, frameshift, indel, in-frame
and missense variants compared to large deletions. This is a feature of
the disease which should be considered when designing targeted
therapies. The abundance of loss-of-function mutations, including
complete gene deletions, in PRPF31 patients has led to a consensus view
that haploinsufficiency is the disease mechanism in this form of RP
(Abu-Safieh et al., 2006; Rio Frio et al., 2008b; Rose and Bhattacharya,
2016). This has influenced approaches for targeted therapies, namely
gene augmentation approaches, which involve replacing a wild-type
copy of the coding sequence of PRPF31 into the subretinal space of
patients. This may not be fully effective in patients with genetic variants
which have a dominant negative effect as well as a haploinsufficiency
effect, and as a result other approaches for treatment may need to be
investigated. These findings are supported by other recent work which
also proposes a combined haploinsufficiency and dominant-negative
disease mechanism in disease associated with PRPF31 mutations
(Valdés-Sánchez et al., 2019). Study of the Prpf31p.A216P/+ mouse has
shown that heterozygous missense mutations in Prpf31 lead to ag-
gregation of both wild-type and mutant protein in the cytoplasm of the
RPE cells of mice, leading to overexpression of HSP70 family proteins
(Valdés-Sánchez et al., 2019). This work suggests that over-expression
of these HSP70 proteins may be a target for therapy in PRPF31 patients,
rather than targeting PRPF31 itself(Valdés-Sánchez et al., 2019).
2. Opportunities for therapies
2.1. Gene augmentation therapy
As a result of the abundance of loss-of-function variants in PRPF31
gene augmentation has been postulated as a potential therapeutic ap-
proach to treat this form of RP(Hafler et al., 2016). The coding se-
quence of PRPF31 is only 1.5 kb, well within the limits of current gene
therapy vectors, and a PRPF31 heterozygous knockout mouse is avail-
able for study, although it only develops very late onset retinal de-
generation which may be more characteristic of age-related macular
degeneration than RP(Farkas et al., 2014). Researchers have begun
preparatory work to define pre-treatment characteristics of RP asso-
ciated with PRPF31 mutations in order to be able to assess the effec-
tiveness of AAV-mediated PRPF31 gene augmentation therapy(Hafler
et al., 2016). These researchers have also patented PRPF31 gene
therapy by AAV2 delivery (International Publication Number
WO2016144892A1) and, shown rescue of key cellular disease pheno-
types including phagocytosis, ciliogenesis, cell morphology and barrier
function in mutant PRPF31+/− RPE derived from patient iPSCs after
deliver of PRPF31(Brydon et al., 2019).
2.2. Antisense oligonucleotide therapy
If the majority of genetic variants have some dominant negative
effect, it is important to consider other potential therapeutic ap-
proaches. These include antisense oligonucleotides (ASOs) which can
bind pre-mRNA or mRNA and modulate splicing of PRPF31 pre-mRNA
or inhibit translation of the mRNA. In addition, siRNAs, shRNAs or
gapmer-style ASOs can be used to completely silence a gene, which
when combined with gene augmentation could potentially correct a
disease with dominant negative effects. This approach has been suc-
cessfully applied to the treatment of RP associated with dominant ne-
gative RHO mutations(Cideciyan et al., 2018). Splice-switching ASOs
Fig. 3. Schematic representation PRPF31 gene, with all reported pathogenic variants labelled above, and total numbers of variants in each intron and exon displayed
as a bar chart below. This shows that exons 7 and 8 are most enriched for pathogenic variants.
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can be used to bind and mask deep intronic variants which introduce
novel splice sites (such as the deep intronic variant in intron 13 re-
ported in Rio Frio et al. (2009)(Rio Frio et al., 2009). Alternatively, they
can be used to induce exon skipping of an in-frame exon (ie an exon
with a multiple of 3 base pairs) carrying a frameshift or null variant, in
order to remove this variant and restore the reading frame. Three of the
fourteen exons in PRPF31 have multiples of 3 base pairs; exons 3, 11
and 14 (Figs. 2 and 3). These are also relatively small exons, and do not
encode functional important domains of the protein (Fig. 2) so they
could be targeted for skipping without removing large or functionally
important regions of the protein. This could have the effect of reverting
a severe, early-onset frameshift or nonsense variant into a less severe
splice or in-frame deletion variant, although the exon skipping would
affect both alleles, mutant and normal, so the effect may be like having
a homozygous exon deletion. According to the genotype-phenotype
data in this study, this could delay age of onset from 8 to 10 years of age
to 25 years of age or later. If this exon skipping approach led to a
disease more like in-frame deletions, this could delay age of diagnosis
(taken as a proxy for loss of peripheral vision) from 25 to 30 years of
age to 47 years of age. This could potentially preserve vision in the
working age of these individuals. This is a promising approach in
theory, and such drugs are already being developed for a range of
previously untreatable genetic conditions.(Scoles and Pulst, 2019;
Levin, 2019; Khan et al., 2019). A clinically available splice-switching
ASO drug (nusinersen) based on 2′O-methoxyethyl phosphorothioate
chemistry has been successfully developed for the treatment of the
neurodegenerative disease spinal muscular atrophy (approved by NICE)
and a similar type of drug (eteplirsen) utilising phosphorodiamidate
morpholino chemistry has been developed for treatment of certain
forms of Duchenne muscular dystrophy(Finkel et al., 2017; Mendell
et al., 2016). Intraocularly delivered ASO drugs are also currently un-
dergoing clinical trials for a specific form of Leber congenital amaurosis
caused by a CEP290 deep intronic mutation (ClinicalTrials.gov
NCT03140969). ASOs are highly versatile drugs, being sequence-spe-
cific in their action, titratable in dosage, and in the setting of a well-
defined and enclosed target organ such as the eye, straightforward to
deliver by direct intravitreal or subretinal injection. However, there are
limited numbers of affected individuals who could be treated by
Fig. 4. (a) Box and whisker plots showing upper and lower limits, median and interquartile range of reported age of onset of RP patients with different types of
variant in PRPF31 (b) Box and whisker plots showing upper and lower limits, median and interquartile range of reported age of diagnosis of RP patients with different
types of variant in PRPF31.
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targeting these regions of PRPF31 (around 27 families).
2.3. Gene independent approaches
As RP associated with PRPF31 is so genetically diverse, (172 dif-
ferent reported variants in 240 different families or simplex cases) gene
independent approaches are extremely attractive alternatives to gene
therapies. These include stem cell therapies and bionic retinal implants.
Stem cell therapies are both gene and disease-agnostic, and can replace
lost retinal cells, whereas gene therapies can only recover function of
intact cells. Stem cell therapies are closest to being effective in re-
placement of the retinal pigment epithelium (RPE), which has no neural
connection. It is more challenging to regenerate functional neural re-
tina. Recent studies have shown promising results in stem cell re-
placement of RPE for treatment of age-related macular degeneration(da
Cruz et al., 2018; Kashani et al., 2018). Bioinic retinae such as the Argus
II(Finn et al., 2018) are able to restore limited light and shape per-
ception in people with end-stage retinal disease and limited to no re-
maining retinal function.
3. Conclusions and future perspective
Gene therapy offers real potential for treatment of a range of cur-
rently untreatable inherited retinal degenerations. As the second most
common cause of adRP, and a relatively small gene, PRPF31 is be-
coming a focus for gene augmentation therapy(Brydon et al., 2019).
This approach assumes a disease mechanism of haploinsufficiency, of
which there is considerable evidence. However, new data presented
here supports the recently proposed theory that, except in cases of
complete exon or gene deletion, dominant negative effects may con-
tribute to disease progression in RP associated with PRPF31 variants
(Valdés-Sánchez et al., 2019), and that gene augmentation therapy may
not be as effective in patients with missense, nonsense or splice muta-
tions compared to whole exon or whole gene deletions. Whilst it is
important to pursue these studies, data from knockout mice must be
interpreted with caution when translating into human studies, and al-
ternatively approaches must also be investigated. These include anti-
sense oligonucleotide therapy targeting suitable exons, and gene-in-
dependent approaches. With several potential therapeutic approaches
under investigation, there is real hope that treatment options for this
disorder will be available to the next generation of patients.
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